SAGE SPECIALTY & REHAB OF LAFAYETTE
1. Target Overview & Investment Thesis
SAGE SPECIALTY & REHAB OF LAFAYETTE is a 31-bed rural/critical access in LAFAYETTE PARISH, LA with $2.2M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 71.0% Medicare, 2.5% Medicaid, and 26.5% commercial.
Thesis: Turnaround. Our ML models identify $178K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -100.1% (+805bps).
| Net Revenue HCRIS | $2.2M |
| Current EBITDA COMPUTED | $-2.4M |
| Operating Margin COMPUTED | -100.0% |
| Occupancy HCRIS | 21.3% |
| Revenue / Bed COMPUTED | $71K |
| Net-to-Gross HCRIS | 58.3% |
| Distress Probability ML | 60.7% |
2. Market Context & Competitive Position
LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -100.0% places it below the state median. Among 132 size-comparable peers (16-62 beds), the median margin is -2.7%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (16-62), prioritizing same-state peers. 132 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| SAGE SPECIALTY & REHAB OF LAFA (Target) | LA | 31 | $2.2M | -100.0% |
| UNIVERSITY HOSPITAL & CLINICS | LA | 52 | $158.9M | -33.4% |
| NEW ORLEANS EAST HOSPITAL | LA | 60 | $77.6M | -29.7% |
| OCHSNER BAYOU LLC | LA | 25 | $76.5M | -0.9% |
| OUR LADY OF THE ANGELS HOSPITA | LA | 36 | $76.2M | -4.9% |
| CENTRAL LOUISIANA SURGICAL HOS | LA | 24 | $69.1M | 7.7% |
| ABBEVILLE GENERAL HOSPITAL | LA | 44 | $68.5M | 3.4% |
| ST. CHARLES PARISH HOSPITAL | LA | 27 | $64.0M | -5.1% |
| AVALA | LA | 21 | $64.0M | 7.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $178K (805bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Denial Rate Reduction | 12.0% | 6.5% | $51K | +230bp | 12mo |
| Net Collection Rate | 93.5% | 97.0% | $46K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $44K | +200bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $27K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $10K | +43bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-2.4M |
| + RCM Uplift | +$178K |
| Pro Forma EBITDA | $-2.2M |
| Current Margin | -100.0% |
| Pro Forma Margin | -100.1% |
| WC Released (1x) | $85K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-3.7M | $-14.0M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-3.7M | $-16.6M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-3.3M | $-17.2M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-3.3M | $-19.7M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-4.0M | $-13.7M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-4.0M | $-16.4M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Heavy Medicare dependence | Medicare comprises 71.0% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement |
| Medium | Low occupancy | At 21.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 60.7% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 132 hospitals with 16-62 beds
- Same-state prioritization (n=133)
- Comp margins: P25=-17.7% / P50=-2.7% / P75=5.4%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.